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Abstract
Background: Polymorphisms in the gene that encodes the human cellular receptor for group B
coxsackieviruses and adenoviruses (HCAR) could be responsible for differences in susceptibility to
infections with these pathogens. Moreover, adenovirus subgroup C-mediated gene therapy could
be influenced by mutations in the coding exons for the aminoterminal immunoglobulin-like 1 (Ig1)
domain, which is the essential component for adenovirus fiber knob binding.
Results: Using two primersets in the adjacent intron sequences, HCAR exons 2 and 3, which
comprise the full-length Ig1 domain, were amplified by polymerase chain reactions in 108
unselected and unrelated healthy Belgian volunteers. After nucleotide sequencing, no
polymorphisms could be demonstrated in the adenovirus-binding Ig1 exons 2 and 3 of the HCAR
gene.
Conclusions: The adenovirus-binding Ig1 domain seems to be a highly conserved region in the
Caucasian population which is a reassuring finding regarding adenovector-based gene therapy.
Background
Recombinant human subgroup C adenoviruses (serotypes
2 and 5) are envisaged as efficient vector delivery systems
in gene therapy because of their ability to transfect a wide
variety of cells [1]. Successful gene delivery requires viral
entry into the target cell via specific receptor-mediated up-
take [2]. For adenoviruses from subgroups A, C, D, E and
F, the human coxsackie-adenovirus receptor (HCAR) pro-
tein functions as the primary high-affinity binding site for
the knob domains of the adenoviral fibers, elongating
from the viral capsid structure. Subsequent interactions
between the viral penton base and cell surface αvβ3 and
αvβ5 integrins induce virus internalization into the target
cells [3].
The gene that encodes HCAR is located on chromosome
21q11.2 and consists of seven exons that are distributed
over an area of 54 kb [4]. After translation a 365-amino
acid (aa) integral membrane glycoprotein is produced,
with an N-terminal exoplasmic domain (218 aa), a single
hydrophobic transmembrane-spanning region (21 aa)
and a highly conserved cytoplasmic tail (107 aa) [5]. The
extracellular portion of the receptor consists of two immu-
noglobulin-like domains: the N-terminal Ig1 is related to
the immunoglobulin V fold and the more C-terminal Ig2
is related to the IgC2 fold. Structural analysis of the mech-
anism of adenovirus binding to HCAR revealed that only
the Ig1 domain (exons 2 and 3) makes contact with the
fiber knob. In contrast, molecular interactions of amino
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ieviruses to HCAR may reside in the Ig2 domain (exons 4
and 5) or in an overlap region between Ig1 and Ig2 [6,7].
In contrast to thorough knowledge about the structure of
HCAR and the viral binding mechanisms, little is known
about the cellular function of this protein. A first report re-
cently described that the mouse homologue of human
CAR, that shows more than 80% similarity with the hu-
man cDNA-sequence, may function naturally as a cell ad-
hesion molecule in the developing mouse brain [8].
HCAR tissue distribution and expression levels are impor-
tant parameters influencing the efficiency of adenovirus-
based gene delivery. Different groups reported a positive
correlation between tissue HCAR levels and adenoviral in-
fectivity [1,2,9]. In vivo, the receptor seems to be expressed
preferentially in epithelial cells of multiple organs. The
highest HCAR-mRNA expression was noted in heart, pan-
creas and brain whereas placenta and skeletal muscle were
HCAR-negative [10].
Fundamental polymorphisms in the coding exons for the
viral binding Ig1 and Ig2 domains, could be responsible
for a variable susceptibility to infections with the respec-
tive pathogens and replication-deficient recombinant ad-
enovectors. HCAR exons 2 and 3, which comprise the Ig1
domain, were therefore screened for mutations in 108 un-
related healthy Belgian individuals.
Results and Discussion
HCAR exons 2 and 3 were PCR-amplified in order to
search for polymorphisms in the adenovirus-binding Ig1
domain. The exon 2 PCR generated an amplicon of 306
bp in length (exon 2 coding region: 167 bp), while a 339
bp fragment was amplified in the exon 3 PCR (exon 3 cod-
ing region: 205 bp). The resulting chromatograms were
analyzed using the SeqMan multiple sequence alignment
tool (LaserGene, DNAStar, Madison, WI). Consensus se-
quences were compared with the corresponding HCAR-
sequences in Genbank using BLAST (Basic Local Align-
ment Search Tool) [12]. All the obtained sequences
showed to be 100 % identical to the sequence in Genbank
(AF200465).
A previous report documented several key residues in the
HCAR Ig1 domain that play an important role in the for-
mation of a high-affinity adenovirus knob-HCAR com-
plex [6]. Remarkable is that the sixteen predicted
interfacial amino acids are wholly conserved among five
different species, as we could deduce from the different
CAR-sequences in Genbank (human: Y07593; mouse:
Y10320; rat: AF109644; pig:AF109646; dog: AF109645).
Mutational analysis of the Ig1 domain of HCAR demon-
strated that single or multiple substitutions of these inter-
facial Ig1 residues could eliminate adenovirus attachment
[6,7]. Polymorphisms in other regions of the HCAR-mol-
ecule might also indirectly affect adenoviral binding. Nev-
ertheless, the Ig1 domain still remains the most important
domain for adenovirus entry which has also been demon-
strated by Wang and Bergelson [13] who stated that HCAR
cytoplasmic and transmembrane domains are not essen-
tial for virus infection.
No polymorphisms could be revealed in exons 2 and 3 of
the HCAR-gene among all 108 tested Caucasian individu-
als. The Ig1 domain that makes contact with the adenovi-
rus fiber knob seems to be a highly conserved area in the
HCAR protein, reinforcing the feasibility of adenovector-
based gene therapy for a Caucasian population. Further
research on other populations might be interesting.
Materials and Methods
DNA-samples of 108 unselected and unrelated Caucasian
Flemish volunteers were collected through a non-invasive
"swish-and-spit" technique, by rinsing the oral cavity with
0.9% saline solution, after which genomic DNA was ex-
tracted using a simple alkaline lysis procedure [11]. In-
formed consent was obtained from all participants.
HCAR exons 2 and 3 (Genbank accession number
AF200465) were amplified separately using polymerase
chain reactions (PCR) with primers chosen in the adjacent
intron sequences 
(HCAR-2F: 5'-TCAATGTGCTGCTTCTGAATG-3'             and
HCAR-2R: 5'-GATAGTTGCACAGACAGCTGC-3'; 
HCAR-3F: 5'-TGTAGCAGCAGGTGTATCCAG-3'             and
HCAR-3R: 5'-CTCTTACTCAGTAACCCGTTAACAC-3')
 Figure 1). Samples were amplified in a final reaction vol-
ume of 50 µl, containing 0.1 µM forward and reverse
primers, 0.5 mM dNTP's, 2.5 mM MgCl2, and 1 U Taq
polymerase (Perkin Elmer/Roche Molecular Systems,
Brussels, Belgium), pH 8.5. Both amplification profiles in-
volved an initial denaturation at 94°C for 5 min, followed
by a three step cycle of 30 sec at 94°C, 30 sec at 56°C (exon
2) or 53°C (exon 3) and 45 sec at 72°C for 35 cycles, and
ending with a final extension of 5 min at 72°C in a Gene-
Amp PCR System 9700 thermal cycler (Perkin Elmer, Fos-
ter City, CA). PCR-products were run on a polyacrylamide
gel, stained with ethidium bromide and visualized under
UV-light. The amplification products were purified using
the QIAquick PCR Purification Kit (Qiagen, Westburg,
The Netherlands) and sequenced in forward and reverse
Figure 1
Position of the forward and reverse primers in intron 1,2 and
3 of the HCAR gene.Page 2 of 3
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direction using the ABI PRISM BigDye Terminator Cycle
Sequencing Reaction Kit on a ABI PRISM 310 DNA se-
quencer (Perkin Elmer Applied Biosystems, Foster City,
CA), according to the manufacturer's instructions.
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